We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
-0.77%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$7.55B
AUM Growth
-$472M
(-5.9%)
Cap. Flow
-$301M
Cap. Flow
% of AUM
-3.99%
Top 10 Holdings %
Top 10 Hldgs %
20.77%
Holding
863
New
59
Increased
344
Reduced
256
Closed
128
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nike
NKE
|
+$25.4M |
| 2 |
AbbVie
ABBV
|
+$21.9M |
| 3 |
KYNB
Kyntra Bio
KYNB
|
+$19.2M |
| 4 |
Waste Management
WM
|
+$19M |
| 5 |
Gilead Sciences
GILD
|
+$17.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$70.2M |
| 2 |
ARRY
Array Biopharma Inc
ARRY
|
+$45.8M |
| 3 |
Biogen
BIIB
|
+$43.3M |
| 4 |
Meta Platforms (Facebook)
META
|
+$24.8M |
| 5 |
Amgen
AMGN
|
+$21.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 31.81% |
| 2 | Technology | 18.27% |
| 3 | Financials | 10.05% |
| 4 | Consumer Discretionary | 9.39% |
| 5 | Communication Services | 7.66% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
RDUS
226
DELISTED
Radius Health, Inc.
RDUS
| $7.83M | 0.1% |
304,025
| – | – |
|
|
FOLD
227
DELISTED
Amicus Therapeutics
FOLD
| $7.83M | 0.1% |
976,000
+90,000
| +10% | +$977K |
|
228
United Airlines
UAL
$38.9B
| $7.81M | 0.1% |
+88,331
| New | +$7.81M |
|
229
Citizens Financial Group
CFG
$30B
| $7.8M | 0.1% |
220,589
-14,007
| -6% | -$489K |
|
230
Travelers Companies
TRV
$81.3B
| $7.73M | 0.1% |
51,968
-4,342
| -8% | -$646K |
|
|
TIF
231
DELISTED
Tiffany & Co.
TIF
| $7.68M | 0.1% |
82,874
+137
| +0.2% | +$12.4K |
|
|
WCG
232
DELISTED
Wellcare Health Plans, Inc.
WCG
| $7.67M | 0.1% |
29,610
+16,171
| +120% | +$4.46M |
|
233
VF Corp
VFC
$6.72B
| $7.58M | 0.1% |
85,144
+19,383
| +29% | +$1.66M |
|
234
Sempra
SRE
$60B
| $7.51M | 0.1% |
101,800
-10,386
| -9% | -$727K |
|
235
Domino's
DPZ
$11.5B
| $7.32M | 0.1% |
29,928
+15,268
| +104% | +$3.78M |
|
236
General Mills
GIS
$19.5B
| $7.27M | 0.1% |
131,856
-52,486
| -28% | -$2.83M |
|
237
Exelon
EXC
$48.4B
| $7.25M | 0.1% |
210,550
-21,471
| -9% | -$721K |
|
|
CTXS
238
DELISTED
Citrix Systems Inc
CTXS
| $7.22M | 0.1% |
74,798
-3,388
| -4% | -$324K |
|
239
US Bancorp
USB
$98.8B
| $7.18M | 0.1% |
129,664
-3,059
| -2% | -$165K |
|
240
GE Aerospace
GE
$375B
| $7.15M | 0.09% |
160,444
-7,823
| -5% | -$368K |
|
241
Nektar Therapeutics
NKTR
$2.39B
| $7.1M | 0.09% |
26,000
-1,283
| -5% | -$471K |
|
242
CenterPoint Energy
CNP
$28.8B
| $7.05M | 0.09% |
233,454
-23,733
| -9% | -$684K |
|
243
Universal Health Services
UHS
$9.8B
| $7.03M | 0.09% |
47,277
+15,920
| +51% | +$2.29M |
|
244
Lear
LEA
$7.2B
| $6.96M | 0.09% |
59,015
+7,031
| +14% | +$855K |
|
245
Aramark
ARMK
$15.2B
| $6.92M | 0.09% |
220,093
+18,965
| +9% | +$533K |
|
|
CERN
246
DELISTED
Cerner Corp
CERN
| $6.92M | 0.09% |
101,485
+1,804
| +2% | +$128K |
|
247
Enanta Pharmaceuticals
ENTA
$378M
| $6.91M | 0.09% |
115,000
+50,000
| +77% | +$3.71M |
|
248
Honeywell
HON
$77.6B
| $6.89M | 0.09% |
43,227
-43,345
| -50% | -$6.89M |
|
|
GTHX
249
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $6.89M | 0.09% |
+302,500
| New | +$9.54M |
|
250
ConocoPhillips
COP
$143B
| $6.87M | 0.09% |
120,493
+3,152
| +3% | +$179K |
|
Similar funds
PCM
A
MGP
LF
SOMRS
BPA
MIM
Candriam SCA's Q3 2019 Portfolio in Review
As of Q3 2019, Candriam SCA held 863 positions worth $7.55B, down 5.9% from $8.02B the previous quarter. Its ten largest holdings account for 21% of the portfolio.
Candriam SCA withdrew a net $301M in Q3 2019, closing 128 positions and reducing 256 holdings. Its most notable exit was Celgene Corp, an estimated $70.2M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 32% of assets, down from 33% a quarter earlier, followed by Technology and Financials.
Against the trend, Candriam SCA opened a new position in Nike worth $27.8M.
- Candriam SCA's largest Q3 2019 buy was Nike: 295,763 shares worth $27.8M.
- Candriam SCA added most to AbbVie in Q3 2019, an estimated $21.9M increase.
- Candriam SCA's biggest Q3 2019 reduction was Biogen, cutting an estimated $43.3M.
- Candriam SCA fully exited Celgene Corp in Q3 2019, selling an estimated $70.2M.
- Candriam SCA's ten largest holdings make up 21% of its $7.55B portfolio in Q3 2019.
- Candriam SCA opened 59 new positions and closed 128 in Q3 2019.
- Candriam SCA's portfolio value fell 5.9% quarter-over-quarter to $7.55B.
Based on Candriam SCA's 13F filing for Q3 2019, filed 21 Oct 2019.